Strategic unmet need Replenish, Inc. targets the retinal therapeutic market with a novel implantable, refillable drug pump for AMD, presenting a compelling opportunity to position advanced delivery solutions to ophthalmology clinics, specialty pharma sponsors, and academic research centers seeking long-acting biotech therapies.

Clinical trial readiness The MicroPump is currently in clinical investigation, indicating a potential near-term need for clinical trial partnerships, investigator-sponsored research, and collaborative ventures with contract research organizations to support trial expansion and data generation.

High-touch sales opportunities The device requires ophthalmic surgical implantation and wireless recharging, suggesting doors open for limited, specialty sales channels, including ophthalmology practices, surgical centers, medical device distributors, and training programs for clinicians.

Financial readiness With reported revenue in the mid-range and prior funding of 10M, there is a foundation for scalable go-to-market activity, potential partnerships with biotech investors, and co-development discussions with pharma sponsors seeking durable long-acting therapies.

Complementary tech stack Existing tech infrastructure (AWS, iCIMS, Joomla, analytics) can support partner and customer relationship management, cloud-based data handling, and digital marketing efforts to reach ophthalmology networks, clinical labs, and biotech innovators efficiently.